Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.22nd Century Group wholly-owned subsidiary 22nd Century Limited has recruited first patients in Phase II-B trial to evaluate its prescription-based smoking cessation product, X-22.
Subscribe to our email newsletter
In the trial, the patients will smoke X-22 for a duration of six weeks time period with an aim to stop smoking by the end of 6 weeks.
X-22 consists of a kit of very low nicotine (VLN) cigarettes made from 22nd Century’s proprietary tobacco.
The trial aims to compare quit rates of patients using X-22 cigarettes with quit rates of those using active control cigarettes with conventional nicotine content.